Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
94,568,251
-
Share change
-
-224,925
-
Total reported value
-
$85,611,699
-
Put/Call ratio
-
1.6%
-
Price per share
-
$0.91
-
Number of holders
-
112
-
Value change
-
-$260,148
-
Number of buys
-
36
-
Number of sells
-
29
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q3 2024
As of 30 Sep 2024,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
112 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
94,568,251 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock, Inc., VANGUARD GROUP INC, Defender Capital, LLC., Logos Global Management LP, RAFFLES ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, MAI Capital Management, and BANK OF AMERICA CORP /DE/.
This page lists
112
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.